Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases

Trends in Pharmacological Sciences

Volumn 29, Issue 4, 2008, Pages 170-174

  Thio, Marco ^a   Blokhuis, Bart R ^a   Nijkamp, Frans P ^a   Redegeld, Frank A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

F 991; IMMUNOGLOBULIN E; IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CELL ACTIVATION; CONTACT SENSITIVITY; ENTERITIS; HUMAN; INFLAMMATORY DISEASE; MAST CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASTHMA; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MAST CELLS; RHINITIS;

EID: 41349097051     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.01.004     Document Type: Article

References (64)

1. Hopper J.E., and Papagiannes E. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell. Immunol. 101 (1986) 122-131
2. Skvortsov V.T., and Gurvich A.E. Relative rates of synthesis of immunoglobulins and light chains in rabbit spleen cells during secondary response. Nature 218 (1968) 377-378
3. Hannam-Harris A.C., and Smith J.L. Free immunoglobulin light chain synthesis by human foetal liver and cord blood lymphocytes. Immunology 43 (1981) 417-423
4. Shapiro A.L., et al. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature 211 (1966) 243-245
5. Bradwell A.R., et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47 (2001) 673-680
6. van der Heijden M., et al. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur. J. Pharmacol. 533 (2006) 319-326
7. Bradwell A.R. In: Bradwell A.R. (Ed). Serum free light chain assays. 1st edn (2003), The Binding Site Ltd
8. Theoharides T.C., and Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann. N. Y. Acad. Sci. 1088 (2006) 78-99
9. Redegeld F.A., et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 8 (2002) 694-701
10. Kraneveld A.D., et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1578-1583
11. Theoharides T.C., et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217 (2007) 65-78
12. Brown J.M., et al. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin. Exp. Allergy 38 (2008) 4-18
13. Biedermann T., et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J. Exp. Med. 192 (2000) 1441-1452
14. van Houwelingen A.H., et al. Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin. Exp. Allergy 37 (2007) 270-275
15. Redegeld F.A., and Nijkamp F.P. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions?. Trends Immunol. 24 (2003) 181-185
16. Paliwal V., et al. Subunits of IgM reconstitute defective contact sensitivity in B-1 cell-deficient xid mice: κ light chains recruit T cells independent of complement. J. Immunol. 169 (2002) 4113-4123
17. Cooper A., and Bluestone R. Free immunoglobulin light chains in connective tissue diseases. Ann. Rheum. Dis. 27 (1968) 537-543
18. Pearce N., et al. How much asthma is really attributable to atopy?. Thorax 54 (1999) 268-272
19. Brightling C.E., et al. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346 (2002) 1699-1705
20. Kraneveld A.D., et al. Key role for mast cells in nonatopic asthma. J. Immunol. 169 (2002) 2044-2053
21. Yu M., et al. Mast cells can promote the development of multiple features of chronic asthma in mice. J. Clin. Invest. 116 (2006) 1633-1641
22. Rijnierse A., et al. TNF-α is crucial for the development of mast cell-dependent colitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G969-G976
23. Rijnierse A., et al. Critical role for mast cells in the pathogenesis of 2,4-dinitrobenzene-induced murine colonic hypersensitivity reaction. J. Immunol. 176 (2006) 4375-4384
24. Rijnierse A., et al. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol. Ther. 116 (2007) 207-235
25. Gottenberg J.E., et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome. Ann. Rheum. Dis. 66 (2007) 23-27
26. Rinker II J.R., et al. Elevated CSF free κ light chains correlate with disability prognosis in multiple sclerosis. Neurology 67 (2006) 1288-1290
27. Lamers K.J., et al. Cerebrospinal fluid free κ light chains versus IgG findings in neurological disorders: qualitative and quantitative measurements. J. Neuroimmunol. 62 (1995) 19-25
28. Goffette S., et al. Detection of oligoclonal free κ chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 75 (2004) 308-310
29. Amin K., et al. Inflammation and structural changes in the airways of patients with primary Sjögren's syndrome. Respir. Med. 95 (2001) 904-910
30. Napoli D.C., and Freeman T.M. Autoimmunity in chronic urticaria and urticarial vasculitis. Curr. Allergy Asthma Rep. 1 (2001) 329-336
31. Christy A.L., and Brown M.A. The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J. Immunol. 179 (2007) 2673-2679
32. Woolley D.E., and Tetlow L.C. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2 (2000) 65-74
33. Solling K., et al. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med. Scand. 209 (1981) 473-477
34. Fagnart O.C., et al. Free κ and λ light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J. Neuroimmunol. 19 (1988) 119-132
35. Elovaara I., et al. Increased occurrence of free immunoglobulin light chains in cerebrospinal fluid and serum in human immunodeficiency virus-1 infection. J. Neuroimmunol. 35 (1991) 65-77
36. Hopper J.E., et al. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin. J. Clin. Immunol. 9 (1989) 338-350
37. Tsai C.Y., et al. Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann. Rheum. Dis. 51 (1992) 168-172
38. Groop L., et al. Urinary excretion of κ light chains in patients with diabetes mellitus. Kidney Int. 37 (1990) 1120-1125
39. Theoharides T.C., and Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 25 (2004) 235-241
40. Conti P., et al. Role of mast cells in tumor growth. Ann. Clin. Lab. Sci. 37 (2007) 315-322
41. Geoffrey R., et al. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J. Immunol. 177 (2006) 7275-7286
42. Nakano T., and Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. J. Immunol. Methods 275 (2003) 9-17
43. Nakano T., et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin. Chem. Lab. Med. 44 (2006) 522-532
44. Contini C., et al. Evidence of cerebrospinal fluid free κ light chains in AIDS patients with Toxoplasma gondii encephalitis. J. Neuroimmunol. 108 (2000) 221-226
45. Nakano T., et al. Antigen-specific free immunoglobulin light-chain antibodies: could it be a new diagnostic marker for patients with allergy?. Clin. Biochem. 39 (2006) 955-959
46. Boivin D., et al. Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin κ light chain. Arch. Biochem. Biophys. 431 (2004) 197-206
47. Sun M., et al. Proteolytic activity of an antibody light chain. J. Immunol. 153 (1994) 5121-5126
48. Paul S., et al. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270 (1995) 15257-15261
49. Thiagarajan P., et al. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 39 (2000) 6459-6465
50. Jokiranta T.S., et al. Nephritogenic λ light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163 (1999) 4590-4596
51. Edmundson A.B., and Ely K.R. Binding of N-formylated chemotactic peptides in crystals of the Mcg light chain dimer: similarities with neutrophil receptors. Mol. Immunol. 22 (1985) 463-475
52. Edmundson A.B., et al. The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. Mol. Immunol. 24 (1987) 915-935
53. Nishimura E., et al. Recombinant light chain of human monoclonal antibody HB4C5 as a potentially useful lung cancer-targeting vehicle. Hum. Antibodies 9 (1999) 111-124
54. Holt L.J., et al. Domain antibodies: proteins for therapy. Trends Biotechnol. 21 (2003) 484-490
55. Colby D.W., et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17616-17621
56. van den Beucken T., et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310 (2001) 591-601
57. Sengul S., et al. Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int. 62 (2002) 1977-1988
58. Zoja C., et al. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp. Nephrol. 7 (1999) 420-428
59. Teng J., et al. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab. Invest. 84 (2004) 440-451
60. Wall J.S., et al. A study of the interactions of an immunoglobulin light chain with artificial and B-lymphocyte membranes. Front. Biosci. 1 (1996) a46-a58
61. Foy S.P., and Matsuuchi L. Association of B lymphocyte antigen receptor polypeptides with multiple chaperone proteins. Immunol. Lett. 78 (2001) 149-160
62. Meixlsperger S., et al. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 26 (2007) 323-333
63. Puxeddu I., and Levi-Schaffer F. Mast cells and eosinophils: the hallmark of asthma. Paediatr. Respir. Rev. 5 Suppl. A (2004) S31-S34
64. Katzmann J.A., et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin. Chem. 48 (2002) 1437-1444